OcupyBioM (hereafter OcupyM) announced on July 10 that its investigational immuno-oncology candidate, Oregovomab, has been shown in domestic clinical settings to significantly extend the survival period of patients with terminal ovarian cancer.
This treatment was administered to a total of 13 terminal ovarian cancer patients under the leadership of Professor Hwang Inhwan of the Department of Hematology and Oncology at Daejeon Eulji University Hospital, after obtaining treatment-use approval from the Ministry of Food and Drug Safety. Cases were confirmed in which patients, whose expected survival was predicted to be only two to three months, were still alive after the six-month clinical period, highlighting the potential of Oregovomab as a therapeutic alternative.
Oregovomab is an immuno-oncology drug that targets the tumor marker cancer antigen 125 (CA125), which is commonly expressed in ovarian cancer. It operates through a completely different mechanism from existing immunotherapies such as PD-(L)1 inhibitors. It is considered suitable for terminal patients due to its low toxicity and its ability to restore immunosuppressed conditions.
An OcupyM representative stated, "Oregovomab could become a new hope for patients who do not respond to existing treatments. In particular, the extension of survival in ovarian cancer patients?where early diagnosis is difficult and effective therapies are lacking?is a very encouraging outcome."
Based on these cases, OcupyM is also reviewing subsequent clinical strategies, including the possibility of combination therapy with existing immunotherapies. Through this, the company plans to assess whether the application can be expanded not only to recurrent ovarian cancer patients but also to first-line treatment groups.
Meanwhile, OcupyM is currently pursuing the acquisition of the listed company Adbiotech.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
